High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer
High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer
复制标题
DOI：
10.1158/0008-5472.can-06-3424
复制
发表时间：
2007-05-15
期刊：
影响因子：
11.2
通讯作者：
Saiki, Ikuo
中科院分区：
文献类型：
--
作者：
Hojo, Shozo;Koizumi, Keiichi;Saiki, Ikuo
CXCL 16是趋化因子超家族的新成员，它以跨膜和可溶性形式存在。其受体CXCR6在CD4（+）T细胞、CD8（+）T细胞和自然杀伤T细胞上检测到。在这里，我们报告了一个显着的相关性CXCL16表达的肿瘤细胞与T细胞浸润和预后的结直肠癌（CRC）。我们首先发现，CXCL16表达在肿瘤组织中比在来自相同CRC患者的正常粘膜中一致上调更多。四种人CRC细胞系也表达CXCL16 mRNA并分泌可溶性CXCL16。接下来，我们通过免疫组织化学检测了CRC标本（n = 58）中CXCL 16的表达和淋巴细胞浸润。CXCL16高表达组（n = 43）的肿瘤浸润性淋巴细胞（TIL）中CD4（+）和CD8（+）的水平显著高于CXCL16低表达组（n = 15）。CXCL16高表达组预后明显好于CXCL16低表达组（P < 0.05）。总的来说，我们的数据表明，肿瘤细胞表达CXCL16增强了TIL的募集，从而使CRC的预后更好。因此，CXCL16是一种新的预后生物标志物，可能有助于开发更有效的CRC治疗策略。
CXCL16 is a new member of the chemokine superfamily, which exists in a transmembrane as well as a soluble form. Its receptor CXCR6 is detected on CD4(+) T cells, CD8(+) T cells, and natural killer T cells. Here, we report a significant correlation of CXCL16 expression by tumor cells with the infiltration of T cells and prognosis in colorectal cancer (CRC). We first found that CXCL16 expression was consistently up-regulated more in tumor tissues than in normal mucosa derived from the same CRC patients. Four human CRC cell lines also expressed CXCL16 mRNA and secreted soluble CXCL16. We next examined the expression of CXCL16 and infiltration of lymphocytes in CRC specimens (n = 58) by immunohistochemistry. CRC patients with high levels of CXCL16 expression (n = 43) had higher levels of CD4(+) and CD8(+) tumor-infiltrating lymphocytes (TIL; P < 0.01) than those with tow levels of CXCL16 expression (n = 15). Furthermore, the high CXCL16 expression group showed significantly better prognosis than the low CXCL16 expression group (P < 0.05). Collectively, our data suggest that the expression of CXCL16 by tumor cells enhances the recruitment of TILs, thereby bringing about a better prognosis in CRC. Thus, CXCL16 is a new prognostic biomarker and may be useful for the development of a more effective therapeutic strategy for CRC.